Metastatic Breast Cancer

No significant survival benefits were found when comparing three CDK4/6 inhibitor combinations during initial treatment for HR-positive, HER2-negative metastatic breast cancer.

Data from the phase 3 DESTINY-Breast06 trial were presented during the 2024 San Antonio Breast Cancer Symposium.

Setbacks happen often in life, but finding gratitude can come at unexpected moments with cancer.

The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in metastatic breast cancer.

A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus endocrine therapy.

An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to hormone therapy.

An Itovebi regimen demonstrated significantly longer progression-free survival compared with placebo in some with metastatic breast cancer.

Trodelvy shows effectiveness in real-world breast cancer treatment, even after receiving Enhertu therapy.

An expert discussed the importance of patients learning about their specific type of breast cancer to understand potential treatment options.

An expert discussed the importance of biomarkers in guiding treatment decisions for patients with metastatic breast cancer.

The Food and Drug Administration (FDA) has approved Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) for certain patients with advanced or metastatic breast cancer.

Martha Carlson shares her experience of overcoming her fears and embarking on a whitewater rafting adventure despite her stage 4 cancer diagnosis.

Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.

Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, without affecting overall quality of life.

Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of life.

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and -ultralow metastatic breast cancer.

A patient with metastatic breast cancer confronts financial toxicity and finds a little glimmer of hope through donating cancer drugs.

Two breast oncologists responded to frequently asked questions about metastatic breast cancer.

A patient with metastatic breast cancer finds that sometimes a single small step leads to unexpected improvement.

Annie Bond, a comedian and survivor of metastatic breast cancer, started making videos on social media to cultivate a community she needed after her diagnosis.

The FDA will speed up their review of Enhertu for HR-positive, HER2-low/ultralow advanced breast cancer that cannot be removed via surgery.

An expert explained the importance of understanding different subtypes of metastatic breast cancer and available treatment options based on biomarker testing.

From “Top Chef’” Shirley Chung and comedian Christina Pazsitzky announcing their diagnoses to Erica Ash’s death from the disease, here is what’s happening in the oncology space this week.

Here are answers to 10 questions patients asked at the CURE® Educated Patient® Metastatic Breast Cancer Summit about scans, treatment and clinical trials.

I’m approaching 10 years with stage 4 breast cancer, and this question tops the “most asked” list.